Inhalation Sciences receives landmark FDA approval for co-financing of its study to validate DissolvIt as a standard research method in the US
(Stockholm, 4 August 2022) The US FDA (Food and Drug Administration) has approved Inhalation Sciences’ proposal for a research study aiming to validate the company’s in vitro lung simulation model DissolvIt[®] as an FDA-recommended dissolution technology, and ultimately a new ‘golden standard’ for dissolution testing for inhaled drugs. The FDA will support and co-finance the study with up to 250 000 USD annually for up to two years. The study will commence in the coming months.The US FDA’s National Center for Toxicological Research has approved ISAB’s research proposal for a study aiming to